NFKB1 and COVID-19: In addition to inhibition of the TNFα, IL-1β and IL-6 induced NF-κB activation, several COVID-19 drugs inhibit the NF-κB activation through disrupting the crosstalk signaling, such as MAPK(JNK/ERK/p38), ANG II-AT1R and ACE2-MAS signaling pathways [22].